- Home
- ELAB
ELAB
Elevai Labs Inc.
as 12-18-2024 9:49am EST
Stocks
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | NEWPORT BEACH |
| Market Cap: | N/A | IPO Year: | 2023 |
| Target Price: | N/A | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -61.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.74 - $778.00 | Next Earning Date: | 11-14-2024 |
| Revenue: | $2,446,161 | Revenue Growth: | 112.17% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Elevai Labs Inc. News
ELAB Breaking Stock News: Dive into ELAB Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation
GlobeNewswire
12 days ago
Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market
GlobeNewswire
14 days ago
Elevai Labs Inc. Announces Record-Breaking Sales Month in 2024 for Elevai Skincare Division
GlobeNewswire
a month ago
Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance
GlobeNewswire
a month ago
Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess
Simply Wall St.
a month ago
Elevai Labs Third Quarter 2024 Earnings: US$0.068 loss per share (vs US$0.078 loss in 3Q 2023)
GlobeNewswire
a month ago
CORRECTION - Elevai Labs Inc.
GlobeNewswire
a month ago
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
Compare ELAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ELAB Elevai Labs Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.